Phase 2 study of tasocitinib for the treatment of plaque psoriasis - ONA
Links shared publicly online about this topic.
- 819total visits
Phase 2 study of tasocitinib for the treatment of plaque psoriasis - ONA
View full resource at oncologynurseadvisor.com
Tags: Psoriasis, Phase 2 Clinical Trial, Pfizer
Most Recently Shared on October 7, 2010 at 4:46 pm By:
Phase 2 study of tasocitinib for the treatment of plaque psoriasis http://goo.gl/fb/itNAQ
Phase 2 study of tasocitinib for the treatment of plaque psoriasis - MPR
empr.com — “Pfizer announced results from its Phase 2 trial of tasocitinib for the treatment of adult patients with moderate-to-severe plaque psoriasis.” View full resource at empr.com
Most Recently Shared on October 7, 2010 at 5:04 pm By:
MPR News: Phase 2 study of tasocitinib for the treatment of plaque psoriasis: Pfizer announced results from its Ph... http://bit.ly/bGnlm9
: Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis | wallstreet:online
wallstreet-online.de — “NEW YORK, October 7, 2010 /PRNewswire/ - Results Presented at the Annual Meeting of the European Academy of Dermatology and Venereology in Gothenburg, Sweden Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy and ...” View full resource at wallstreet-online.de
Most Recently Shared on October 7, 2010 at 3:35 pm By:
Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moder... http://bit.ly/9xVZyZ
Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting
news-medical.net — “New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a favorable benefit-risk profile for up to three years of” View full resource at news-medical.net
Most Recently Shared on August 10, 2010 at 9:54 am By:
Three-year efficacy data on STELARA for psoriasis presented at American Academy of Dermatology meeting: New study ... http://bit.ly/cmjeQf
Phase 2b study of apremilast for treatment of plaque-type psoriasis - MPR
empr.com — “Celgene announced clinical data from its Phase 2b study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005).” View full resource at empr.com
Most Recently Shared on December 16, 2009 at 7:18 pm By:
MPR News: Phase 2b study of apremilast for treatment of plaque-type psoriasis: Celgene announced clinical data from... http://bit.ly/5SXb69
Advertisement
